Reduction in interaction between cGMP and cAMP in dog ventricular myocytes with hypertrophic failure

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 3 58-3, 2005, Pages

  Zhang, Qihang ^a   Lazar, Michael ^a   Molino, Bruno ^a   Rodriguez, Roberto ^a   Davidov, Tomer ^a   Su, Jun ^a   Tse, James ^a   Weiss, Harvey R ^a   Scholz, Peter M ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Adenosine 5 cyclic monophosphate; Canine; Cardiac; Guanosine 5 cyclic monophosphate; Heart; Hypertrophy; Phosphodiesterase

Indexed keywords

8 BROMO CYCLIC GMP; 9 (2 HYDROXY 3 NONYL)ADENINE; CYCLIC AMP; CYCLIC GMP; MILRINONE; PHOSPHODIESTERASE; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; ENZYME ACTIVITY; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; SECOND MESSENGER; SIGNAL TRANSDUCTION;

ADENINE; ANIMALS; BODY WEIGHT; CARDIOTONIC AGENTS; CYCLIC AMP; CYCLIC GMP; DOGS; DRUG INTERACTIONS; ENZYME INHIBITORS; HEART FAILURE, CONGESTIVE; HYPERTROPHY, LEFT VENTRICULAR; MILRINONE; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; ORGAN SIZE; SIGNAL TRANSDUCTION;

EID: 23944455329     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01234.2003     Document Type: Article

References (35)

1. Bohm M, Reiger B, Schwinger RHG, and Erdmann E. cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in non-failing and failing myocardium. Cardiovasc Res 28: 1713-1719, 1994.
2. Brodde OE. β-Adrenergic receptors in failing human myocardium. Basic Res Cardiol 91, Suppl II: 35-40, 1996.
3. Cornwell TL, Arnold E, Boerth NJ, and Lincoln TM. Inhibition of smooth muscle cell growth by nitric oxide and activation of cAMP-dependent protein kinase by cGMP. Am J Physiol Cell Physiol 267: C1405-C1413, 1994.
4. Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol 108: 671-680, 2001.
5. Gustafsson AB and Brunton LL. Attenuation of cAMP accumulation in adult rat cardiac fibroblasts by IL-1β and NO: role of cGMP-stimulated PDE2. Am J Physiol Cell Physiol 283: C463-C471, 2002.
6. Hannan RD, Jenkins A, Jenkins A, and Brandenburger Y. Cardiac-hypertrophy: a matter of translation. Clin Exp Pharmacol Physiol 30: 517-527, 2003.
7. Huang MW, Leone RJ Jr, Weiss HR, Tse J, and Scholz PM. Effects of beta-adrenoceptor stimulation on pacing-induced failure of dog hypertrophic hearts. Clin Exp Pharmacol Physiol 27: 202-207, 2000.
8. Huang MW, Weiss HR, Tse J, Leone RJ Jr, and Scholz PM. Pacing-induced cardiac failure of hypertrophic hearts: effects of cyclic GMP reduction. J Surg Res 86: 89-96, 1999.
9. Joe EK, Schussheim AE, Longrois D, Maki T, Kelly RA, Smith TW, and Balligand JL. Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS): mechanisms of contractile depression by nitric oxide. J Mol Cell Cardiol 30: 303-315, 1998.
10. Klein C. Nitric oxide and the other cyclic nucleotide. Cell Signal 14: 493-498, 2002.
11. Kojda G and Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 41: 514-523, 1999.
12. Kwan HY, Huang Y, and Yao X. Store-operated calcium entry in vascular endothelial cells is inhibited by cGMP via a protein kinase G-dependent mechanism. J Biol Chem 275: 6758-6763, 2000.
13. Leone RJ Jr, Straznicka M, Scholz PM, and Weiss HR. Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts. Basic Res Cardiol 95: 28-38, 2000.
14. Lorell BH and Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102: 470-479, 2000.
15. Movsesian MA and Alharethi R. Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy. Expert Opin Investig Drugs 11: 1529-1536, 2002.
16. 2 ACh receptor. Am J Physiol Cell Physiol 281: C1251-C1258, 2001.
17. Ritter O and Neyses L. The molecular basis of myocardial hypertrophy and heart failure. Trends Mol Med 9: 313-321, 2003.
18. Sato N, Asai K, Okumura S, Takagi G, Shannon RP, Fujita-Yamaguchi Y, Ishikawa Y, Vatner SF, and Vatner DE. Mechanisms of desensitization to a PDE inhibitor (milrinone) in conscious dogs with heart failure. Am J Physiol Heart Circ Physiol 276: H1699-H1705, 1999.
19. Scholz PM, Grover GJ, Mackenzie JW, and Weiss HR. Regional oxygen supply and consumption balance in experimental left ventricular hypertrophy. Basic Res Cardiol 85: 575-584, 1990.
20. Scholz PM, Upsher ME, Eliades E, Kedem J, and Weiss HR. Alteration in the regional β-adrenergic system in experimental left ventricular hypertrophy. Cardiovasc Res 24: 65-71, 1990.
21. Shah AM and MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49-86, 2000.
22. Shahid M and Nicholson CD. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram. Naunyn Schmiedebergs Arch Pharmacol 342: 698-705, 1990.
23. Sperelakis N, Tohse N, Ohya Y, and Masuda H. Cyclic GMP regulation of calcium slow channels in cardiac muscle and vascular smooth muscle cells. Adv Pharmacol 26: 217-252, 1994.
24. 2+ current in rat ventricular myocytes. Circ Res 77: 803-812, 1995.
25. 1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy. Mol Cell Biochem 205: 67-73, 2000.
26. Ungureanu-Longrois D, Bezie Y, Perret C, and Laurent S. Effects of exogenous and endogenous nitric oxide on the contractile function of cultured chick embryo ventricular myocytes. J Mol Cell Cardiol 29: 677-687, 1997.
27. Vatner DE, Homey CL, Sit SP, Manders WT, and Vatner SF. Effects of pressure-overload left ventricular hypertrophy on β-adrenergic receptors and responsiveness to catecholamines. J Clin Invest 73: 1473-1482, 1984.
28. Vila-Petroff MG, Younes A, Egan J, Lakatta EG, and Sollott SJ. Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ Res 84: 1020-1031, 1999.
29. Wallukat G. The beta-adrenergic receptors. Herz 27: 683-690, 2002.
30. Weiss HE, Lazar MJ, Punjabi K, Tse J, and Scholz PM. Negative functional effects of cyclic GMP are altered by cyclic AMP phosphodiesterases in rabbit cardiac myocytes. Eur J Pharmacol 481: 25-31, 2003.
31. Weiss HR, Gong GX, Straznicka M, Yan L, Tse J, and Scholz PM. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic-AMP phosphodiesterases. Can J Physiol Pharmacol 77: 422-431, 1999.
32. Wollert KC and Drexler H. Regulation of cardiac remodeling by nitric oxide: focus on cardiac myocyte hypertrophy and apoptosis. Heart Fail Rev 7: 317-325, 2002.
33. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E, Trautwein C, Lohmann SM, and Drexler H. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 39: 87-92, 2002.
34. Yarbrough WM and Spinale FG. Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol 10: 77-86, 2003.
35. 2+-ATPase. Pharmacology 64: 106-112, 2002.